UNSPSC 51351504: Edogestrone

This classification denotes a therapeutic progestin with the molecular formula C26H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9014UFK50C, chemically known as 17-hydroxy-6-methylpregn-5-ene-3,20-dione cyclic 3-(ethylene acetal) acetate but generally known as edogestrone, which bears US NIH Compound Identifier 101860. European Medicines Agency schedules Edogestrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06459MIG. The term EDOGESTRONE is an International Non-Proprietary Name.

UNSPSC 51351504 Edogestrone is a Commodity code for a specific pharmaceutical active ingredient, though recent state and local procurement under this designation reflects broader generic pharmaceutical supply agreements rather than edogestrone-specific purchases. State and local governments buy generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and authorized wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body active under this code, operating cooperative agreements that serve participating state agencies, local government facilities, and member states including Oregon. Vendors supply comprehensive pharmaceutical product lines through authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) rather than direct-to-agency delivery, and must maintain current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, hold minimum insurance of $5 million commercial general liability per occurrence, and commit to specific pricing structures (flat price, net price, or WAC-minus formats) with performance penalties of $200 to $1,500 per violation.

The code shows activity concentrated in the upper Midwest and Pacific Northwest through the MMCAP cooperative, which aligns with Minnesota's administrative role and Oregon's participation. MMCAP issued an RFP (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026. Evaluation weights heavily price competitiveness (75 percent), with secondary weight on fixed pricing (10 percent), EDI capability (5 percent), administrative compliance (5 percent), and administrative fee acceptance (5 percent). All products must be available in the marketplace by May 15, 2026, vendors must maintain contractual relationships with at least two of the three authorized wholesalers, and agreements carry a two-year initial term with optional extensions at MMCAP's discretion. Specific award values are not disclosed in the solicitation.